Loading patent…
AssigneeALX Oncology Inc.
InventorsJaume PONS, Laura DEMING, Corey GOODMAN, Bang Janet SIM, Steven Elliot KAUDER, Hong WAN, Tracy Chia-Chien KUO
Estimating the term…
The present disclosure features signal-regulatory protein a (SIRPα) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The SIRP-α constructs include a high affinity SIRP-α D1 domain or variant thereof that binds CD47 with higher affinity than a wild-type SIRP-α. The SIRP-α polypeptides or constructs include a SIRP-α D1 variant fused to an Fc domain monomer, a human serum albumin (HSA), an albumin-binding peptide, or a polyethylene glycol (PEG) polymer. Compositions provided herein include (i) a polypeptide including a signal-regulatory protein a (SIRP-α) D1 variant and (ii) an antibody.
1-156. (canceled)
A polypeptide, comprising:
A pharmaceutical composition comprising
A method of treating an individual having cancer, the method comprising administering to the individual a pharmaceutical composition comprising a polypeptide and a pharmaceutically acceptable excipient, wherein the polypeptide comprises
A method of treating an individual having cancer, the method comprising administering to the individual a pharmaceutical composition comprising a dimer and a pharmaceutically acceptable excipient, wherein the dimer comprises a polypeptide that comprises:
A dimer comprising a polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:
A nucleic acid encoding a polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:
A pharmaceutical composition comprising a polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:
A pharmaceutical composition comprising (a) a dimer that comprises a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
A method of treating an individual having cancer, the method comprising administering to the individual a pharmaceutical composition comprising a polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:
A method of treating an individual having cancer, the method comprising administering to the individual a pharmaceutical composition comprising a dimer and a pharmaceutically acceptable excipient, wherein the dimer comprises a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
A polypeptide, comprising:
A pharmaceutical composition comprising
A method of treating an individual having cancer, the method comprising administering to the individual a pharmaceutical composition comprising a polypeptide and a pharmaceutical excipient, wherein the polypeptide comprises
A method of treating an individual having cancer, the method comprising administering to the individual a pharmaceutical composition comprising a dimer and a pharmaceutically acceptable excipient, wherein the dimer comprises a polypeptide that comprises
A dimer comprising a polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:
A nucleic acid encoding a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
A pharmaceutical composition comprising a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
A pharmaceutical composition comprising (a) a dimer that comprises a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
A method of treating an individual having cancer, the method comprising administering to the individual a pharmaceutical composition comprising a polypeptide that comprises the amino acid sequence of SEQ ID NO:
A method of treating an individual having cancer, the method comprising administering to the individual a pharmaceutical composition comprising a dimer and a pharmaceutically acceptable excipient, wherein the dimer comprises a polypeptide comprising the amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.